Key facts
- Acionna Therapeutics’s last known valuation is $15.7M (Apr 2025).
- It has raised $9.8M; the latest was Seed Round ($9.8M) in Apr 2025.
- Notable investors include Oxford Science Enterprises.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Acionna Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Acionna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Acionna Therapeutics
Developer of novel therapeutics intended to target the neuroimmune cascade to improve synaptic function. The company is harnessing the neuroimmune system to tackle Alzheimer's disease and other central nervous system disorders, providing patients with effective therapies.
- Sector
- Healthcare
- HQ
- Huntingdon, United Kingdom
- Founded
- 2025
- Ownership
- Privately Held (backing)
Acionna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acionna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acionna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.